was added to 5 mg (43 nmol) of β -galactosidase, which was 20: 1 molar ratio of biotin: β -galactosidase. The mixture was capped and rocked end over end for 60 min at room temperature.
The sample was applied to a 0.7 X 15 cm Sephadex G-25 column, eluted with 10 ml of 0.01 M PBS/7.4 at 0.5 ml/min, and 0.5 ml fractions were collected. The 3 fractions comprising the first A280 peak were pooled, the protein concentration was determined, and the biotin-LC-LC-β -galactosidase ( Figure 1A , reaction II) was stored at -20C. The enzymatic activity of β -galactosidase or biotinylated beta-gal (biotin-LC-LC-β-galactosidase) was measured with either the spectrophotometric method or the Beta-Glo luminescence assay system.
The molar ratio of sulfo-NHS-LC-LC-biotin to β -galactosidase was determined to yield 8 of 2-(4'-hydroxyazobenzene)benzoic acid (HABA) to avidin by absorbance at 500 nm with an extinction coefficient of 34 mM -1 . The displacement of HABA from avidin is proportional to the biotin content in the biotin-LC-LC-β -galactosidase.
The β -galactosidase/8D3 conjugate, also designated β-gal-8D3 (Figure 1 , reaction III),
was formed by mixing a 1:1 molar ratio of biotin-LC-LC-β -galactosidase and the 8D3/SA conjugate at 15 min at room temperature. There was no loss in β -galactosidase enzyme activity following mono-biotinylation and attachment to the 8D3/SA conjugate ( Figure 1C ).
Brain delivery of β -galactosidase and β -galactosidase/8D3 in adult mice
Adult female BALB/c mice weighing 20-25 g (Charles River Laboratories,Wilmington, MA) were anesthetized with 100 mg/kg ketamine and 10 mg/kg xylazine intra-peritoneal. The mice were injected via the jugular vein with either unconjugated β -galactosidase or the β-gal-8D3 conjugate. In the high dose treatment, mice were administered either (a) 150 µg/mouse of unconjugated β -galactosidase, or (b) 150 µg/mouse of biotinylated β -galactosidase conjugated to 300 µg/mouse of 8D3/SA. In the low dose treatment, mice were administered either (a) 15 µg/mouse of unconjugated β -galactosidase, or (b) 15 µg/mouse of biotinylated β -galactosidase conjugated to 30 µg/mouse of 8D3/SA. The mice were sacrificed at either 1 or 4 hours after intravenous (IV) injection. The brain, liver, spleen, heart and kidney were removed, weighed and frozen on dry ice. The blood from each mouse was collected, heparinized and stored at -20C. Organs and blood were also removed from un-injected mice to determine the activity of endogenous β -galactosidase at neutral pH.
This article has not been copyedited and formatted. The final version may differ from this version. The spectrophotometric assay for β -galactosidase enzyme activity (β-galactosidase Enzyme Assay System, Promega) was not used owing to interference in the absorbance readings by endogenous tissue pigments. Enzyme activity was measured with Promega Beta-Glo luminescence assay system. The tissue was extracted with Promega lysis buffer at a ratio of 2 ml buffer to 0.5 g tissue, followed by homogenization with a Brinkmann Polytron PT3000. The homogenate was centrifuged for 10 min at 12,000 g, and the supernatant was used to measure β -galactosidase activity with the Promega Beta-Glo assay solution at pH=7.6. The mixture was incubated in the dark at room temperature for 1 hour. The relative light units (RLU) were measured with a luminometer (EG&G Berthold, Oak Ridge, TN), and the RLU was converted to milliunits (mU) of enzyme activity based on a β -galactosidase standard curve. The protein content in the organ extract was measured with the BCA reagent. Organ enzyme activity was measured as: (a) mU/mg protein, (b) mU/gram organ weight, or (c) % injected dose (ID)/g organ weight. The ID was computed from the known specific activity (mU/µg) of the unconjugated β -galactosidase or the β-gal-8D3 conjugate. The endogenous β -galactosidase enzyme activity in un-injected mice was also measured in each organ.
Brain β -galactosidase histochemistry
Mice were anesthetized and injected with maximal doses of either of unconjugated β -galactosidase (300 µg/mouse) or the β-gal-8D3 conjugate (300 µg/mouse of biotin-LC-LC-β-galactosidase mixed with 600 µg/mouse of 8D3/SA conjugate) via the jugular vein. At 60 min after IV injection, the brain plasma volume was cleared with a 4 min infusion of 4 mL cold PBS into the ascending aorta at a rate of 1 mL/min, followed by a 20 min perfusion of 20 ml of A dot-blot assay was developed to determine the minimal β -galactosidase enzyme activity that could be detected with a colorimetric histochemical assay. Enzyme (100 uL) was spotted with a Biorad dot blot apparatus in a 3 mm circle to nitrocellulose filter paper in the following amounts: 68, 6.8, 0.68, 0.068, and 0.0068 mU with or without fixation of the blotted filter paper in 0.2% glutaraldehyde in 0.1 M Na 2 HPO 4 /7.4/2 mM MgCl 2 for 2 min. Enzyme activity in the filter paper was measured with the colorimetric technique (β-galactosidase Enzyme Assay System, Promega). The amount of enzyme that was barely detected by eye was >2 mU with fixation and >1 mU without fixation. A 40 micron section of mouse brain weighs approximately 1 mg. Therefore, it would be necessary to achieve a12 Therefore, GTP enzyme activity in the post-vascular supernatant approximates the GTP enzyme activity in the starting brain homogenate; however, the ratio of GTP enzyme activity in the vascular pellet, relative to the brain homogenate, is a quantitative measure of the extent to which the post-vascular supernatant has been depleted of the microvascular component of brain (Triguero et al, 1990 ).
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RESULTS
Following the IV administration of the low dose (15 ug/mouse) of the unconjugated β -galactosidase, the enzyme was rapidly cleared from blood by liver, spleen, and kidney ( Figure 2 ).
The enzyme was cleared by liver and spleen after the IV administration of the high dose (150 ug/mouse) of the unconjugated β -galactosidase ( Figure 3 ). The high dose caused minimal saturation of the uptake of the unconjugated enzyme by liver and spleen. The 60 min enzyme activity in liver was 1,144 ± 190 mU/g (7.7 ± 0.9 mU/mg protein) and 41,086 ± 8,497 mU/g (386 ± 84 mU/mg protein) after the IV injection of the low dose and high dose, respectively, of unconjugated enzyme. The 60 min enzyme activity in spleen was 3,038 ± 384 mU/g (21 ± 3 mU/mg protein) and 32,686 ± 5,777 mU/g (367 ± 68 mU/mg protein) after the IV injection of the low dose and high dose, respectively, of unconjugated enzyme. The brain uptake of the unconjugated enzyme was minimal at both the low dose (Figure 2 , inset) and the high dose of enzyme ( Figure 3 , inset). The 60 min enzyme activity in brain was 121 ± 3 mU/g (2.0 ± 0.1 mU/mg protein) and 116 ± 26 mU/g (2.8 ± 0.6 mU/mg protein) after the IV injection of the low dose and high dose, respectively, and both values approximated the endogenous enzyme activity in the un-injected mouse brain, 85 ± 3 mU/g (1.5 ± 0.1 mU/mg protein).
Conjugation of the enzyme to the TfRMAb accelerated uptake in peripheral tissues and the largest increases in uptake were observed for liver and spleen at the low dose of enzyme (Figure 2 ). At the low dose, the brain uptake of β -galactosidase was increased 10-fold following conjugation to the TfRMAb (Figure 2 , inset). At the high dose, the uptake of the enzymeTfRMAb conjugate by liver and spleen showed saturation (Figure 3 ), whereas the brain uptake was still increased 10-fold following conjugation to the TfRMAb (Figure 3 , inset).
This article has not been copyedited and formatted. The final version may differ from this version. The β -galactosidase enzyme activity was rapidly eliminated from mouse organs in vivo, and organ enzyme activity at 4 hours after an IV injection was no greater than the endogenous organ enzyme activity at the high dose injection (Table 1 ). The rapid clearance of β -galactosidase from blood in the adult mouse is shown in Table 2 , which indicates the blood concentration of the unconjugated enzyme is <1% injected dose (ID)/mL blood at 60 minutes after IV injection.
The brain uptake of the unconjugated β -galactosidase or the β -galactosidase-TfRMAb conjugate was measured with histochemistry after treatment with maximal doses (Methods). At 60 min after an IV injection of the unconugated enzyme, there is no measurable enzyme activity in brain in either the parenchymal or capillary compartment ( Figure 4C ). At 60 min after an IV injection of the high dose of the β -galactosidase-TfRMAb conjugate, the enzyme product is detected by histochemistry in the capillary compartment throughout the entire brain, including cerebellum (data not shown) and a representative low magnification view is shown in Figure 4B .
High magnification microscopy ( Figure 4A ) shows the enzyme within the microvascular endothelium; this enzyme activity is localized to the intra-endothelial compartment, and not the plasma compartment, because the brain was saline cleared prior to perfusion fixation for histochemistry (Methods). The brain vasculature was effectively cleared of enzyme as shown by the absence of vascular enzyme product following injection of the un-conjugated enzyme ( Figure   4C ). Histochemical product in brain parenchyma was not clearly detectable, because the brain β - (Table 3) . Measurement of the activity of a brain microvascular enriched enzyme, GTP, showed that the vascular pellet GTP activity was 16-fold greater than GTP activity in the brain homogenate, indicating the post-vascular supernatant was 94% depleted of the capillary compartment (Table 3) .
DISCUSSION
The results of this study are consistent with the following conclusions. First, unconjugated β -galactosidase is rapidly cleared from blood in vivo (Table 2) , owing to rapid uptake of the unconjugated enzyme by liver and spleen (Figures 2-3) . Second, once inside cells, β -galactosidase is rapidly degraded in vivo such that 99% of the organ enzyme activity is lost at 4 hours after an intravenous injection (Table 1) . Third, the 116 kDa β -galactosidase ( Figure 1B) can be conjugated to the 8D3 TfRMAb without loss of enzyme activity ( Figure 1C) . Fourth, there is minimal brain uptake of the unconjugated β -galactosidase, but there is a 10-fold increase in brain uptake of enzyme following conjugation to the 8D3 TfRMAb (Table 1, Figures 2-3 ).
The β -galactosidase is rapidly removed from the blood due to the avid uptake of the enzyme by liver and spleen (Figures 2-3) , which confirms the earlier observation of Onodera et al (1983) . The blood concentration of the β -galactosidase/TfRMAb is 5-to 10-fold higher than the corresponding blood concentration of unconjugated β -galactosidase at 1-4 hours after injection ( Table 2 ). The delayed clearance of the enzyme/TfRMAb conjugate may be related to the larger size of the enzyme/TfRMAb conjugate, as compared to the unconjugated enzyme.
Following transport of the unconjugated β -galactosidase into cells, the enzyme is rapidly degraded in vivo, and the organ enzyme activity at 4 hours after intravenous injection is no greater than the endogenous enzyme activity (Table 1 ). In liver, the organ enzyme activity following intravenous injection of unconjugated β -galactosidase decreases 275-fold between 1 and 4 hours after administration (Table 1) . This observation confirms an earlier study on the rapid degradation of bacterial β -galactosidase by mouse organs in vivo (Scherpereel et al, 2001 ).
In contrast to the rapid uptake of the unconjugated enzyme by peripheral tissues, the brain uptake of unconjugated β -galactosidase is nil, as shown by the absence of any change in Figure 3A and B). This histochemical assay demonstrates the targeting of the enzyme to the BBB compartment of brain, whereas no measurable enzyme activity was detected in the endothelial compartment following intravenous injection of the unconjugated enzyme ( Figure   3C ). The histochemical product in the endothelial compartment of brain was not due to entrapment of the enzyme in the blood compartment because the brain was saline cleared prior to perfusion fixation for the histochemistry (Methods). The adequacy of the saline clearance is demonstrated by the inability to detect histochemical product in the capillary compartment following injection of the unconjugated enzyme ( Figure 4C ).
This article has not been copyedited and formatted. The final version may differ from this version. It is possible to detect the β -galactosidase enzyme activity in the endothelial cell of brain because this compartment has such a small volume. The intra-endothelial compartment in brain, < 1 µ l/g, is about 1000-fold lower than the extra-vascular volume in brain (Pardridge, 2001) .
Therefore, when the enzyme-TfRMAb conjugate passes through the endothelial compartment, the enzyme activity is concentrated in the small endothelial volume, which allows for light microscopic histochemical detection. An identical intra-endothelial vascular staining pattern was reported previously following systemic administration of a TfRMAb conjugated to 5 nm gold (Bickel et al, 1994) . The transport of the β -galactosidase/TfRMAb conjugate across the BBB and into brain parenchyma was demonstrated with the capillary depletion technique (Methods) as shown in Table 3 . The β -galactosidase enzyme activity in the post-vascular supernatant is > 90%
of the corresponding enzyme activity in the homogenate following IV injection of the β -galactosidase-TfRMAb conjugate (Table 3) . Therefore, more than 90% of the β -galactosidase/8D3 conjugate that enters into the endothelial compartment passes through the BBB to enter brain parenchyma. This observation is in accord with prior work, which showed that >80% of the TfRMAb undergoes transcytosis through the BBB and into brain parenchyma within a 10-minute internal carotid artery perfusion of brain (Skarlatos et al, 1995) .
The β -galactosidase enzyme activity in brain, and in other organs, returns to the endogenous level by 4 hours after an intravenous injection of the enzyme-TfRMAb conjugate (Table 1) , which confirms earlier work by Scherpereel et al (2001) . This rapid inactivation of either the unconjugated enzyme or of the β -galactosidase-TfRMAb conjugate contrasts with prior work showing peak β -galactosidase enzyme activity in brain is observed between 4 and 8 hours following the IV injection in mice of a fusion protein of β -galactosidase and the cationic peptide of the TAT protein of the human immunodeficiency virus (Schwarze et al, 1999) .
This article has not been copyedited and formatted. The final version may differ from this version. Conjugation of the cationic TAT peptide to a protein causes a >20-fold increase in the organ clearance of the protein in vivo (Lee and Pardridge, 2001) . Therefore, a conjugate of the TAT cationic peptide and β -galactosidase might be rapidly eliminated from blood and organs such as brain in vivo.
In conclusion, these studies demonstrate the feasibility of delivering enzymes across the BBB with receptor-specific monoclonal antibodies that cross the BBB via endogenous receptor- Data are means ± SE (n=3 mice). The β-galactosidase enzyme activity and the γGTP enzyme activity were measured in brain fractions removed 60 min after an intravenous injection of 150
